An Ephemeral Evaluation Study to Find Which Antidiabetic Can be a Better Hypolipidemic-Metformin 850 mg Twice Daily or Teneligliptin 20 mg once Daily and Metformin 500 mg Twice Daily Combination
Abstract:
Background: The
global scenario of Diabetes Mellitus is worsening every day irrespective of so
many positive moves to mitigate it by WHO guided Health awareness programs and
treatment protocols. Even now health professionals are engaged in managing its complications
rather than treatment as such. A major portion of sufferers of this deadly
disease need attention to reduce the sequelae of insulin insensitivity or
insulin resistance like dysfunction in lipid, carbohydrate, and protein
metabolism. To achieve the same, it is unavoidable to increase the pill count.
Most of the drugs can’t be boxed into fixed-dose combinations. Choosing a drug
with a pleiotropic effect for a disease is the need of the hour. Both study
drugs are known for their pleiotropic effects. The study drug used is metformin
higher dose of 850 mg twice daily against teneligliptin (DPP4 Inhibitor) 20 mg
once daily with metformin 500mg twice daily combination. This study was
conducted to find which antidiabetic can better act as hypolipidemic as well. Method:
The study tenure was from May 2020 – October 2020, a total of 6 months.
Overall, one hundred and sixty patients were assessed; among them hundred
members were selected and ninety-one completed the study. The members were
included as per the inclusion criteria. Research significance: This study aims
to explore the synergistic effects of combining Teneligliptin 20 mg once daily
with Metformin 500 mg twice daily on lipid profile improvement in patients with
Type 2 Diabetes Mellitus (T2DM). While Metformin is a well-established
first-line treatment, its efficacy at higher doses may come with increased side
effects. By integrating Teneligliptin, a DPP-4 inhibitor, with Metformin at a
moderate dose, we hypothesize that this combination will not only provide
effective glycemic control but also offer superior lipid profile management.
The findings could suggest a more effective and safer therapeutic strategy,
reducing the need for higher Metformin doses and minimizing associated risks.
Therefore, the combination of Teneligliptin with Metformin is a promising
therapeutic approach for T2DM management.
References:
[1]. Saeedi, P.,
Peterson, I., Salpea, P., et al. 2019, Global and regional diabetes prevalence
estimates for 2019 and projections for 2030 and 2045, Results from the
International Diabetes Federation Diabetes Atlas. Diabetes Research and
Clinical Practice, 157, 107843. https://doi.org/10.1016/j.diabres.2019.107843
[2]. Leon, B.
M., & Maddox, T. M. 2015, Diabetes and cardiovascular disease:
Epidemiology, biological mechanisms, treatment recommendations, and future
research. World Journal of Diabetes, 6(13), 1246–1258. https://doi.org/10.4239/wjd.v6.i13.1246
[3]. Polonsky,
W. H., & Henry, R. R. 2016, Poor medication adherence in type 2 diabetes:
Recognizing the scope of the problem and its key contributors. Patient
Preference and Adherence, 10, 1299–1307. https://doi.org/10.2147/PPA.S106821
[4]. Ranjbar,
T., Nekooeian, A. A., Tanideh, N., et al. 2020, A comparison of the effects of
Stevia extract and metformin on metabolic syndrome indices in rats fed with a
high-fat, high-sucrose diet. Journal of Food Biochemistry, 44(8),
e13242. https://doi.org/10.1111/jfbc.13242
[5]. Agarwal,
P., Jindal, C., & Sapakal, V. 2018, Efficacy and safety of teneligliptin in
Indian patients with inadequately controlled type 2 diabetes mellitus: A
randomized, double-blind study. Indian Journal of Endocrinology and
Metabolism, 22(1), 41-46. https://doi.org/10.4103/ijem.IJEM_147_17
[6]. Ji, L., Ma,
J., Lu, W., Liu, J., Zeng, J. E., Yang, J., Li, W., Zhang, X., Xiao, X.,
Takayanagi, G., & Wang, Y. 2021, Phase III, randomized, double-blind,
placebo-controlled study to evaluate the efficacy and safety of teneligliptin
monotherapy in Chinese patients with type 2 diabetes mellitus inadequately
controlled with diet and exercise. Journal of Diabetes Investigation, 12(4),
537-545. https://doi.org/10.1111/jdi.13418
[7]. Panchal, J.
S., & Panchal, M. R. 2018, Effect of teneligliptin and metformin on
glycemic control and weight in patients with type 2 diabetes: A retrospective
study. Journal of Clinical and Diagnostic Research, 12(1), OC07-OC10. https://doi.org/10.7860/JCDR/2018/28002.11043
[8].
Pryor, R., & Cabreiro, F. 2015, Repurposing
metformin: An old drug with new tricks in its binding pockets. Biochemical
Journal, 471(3), 307–322. https://doi.org/10.1042/BJ20150618
[9]. Nauck, M.
A., & Meier, J. J. 2018, Incretin hormones: Their role in health and
disease. Diabetes, Obesity and Metabolism, 20(S1), 5-21. https://doi.org/10.1111/dom.13129
[10]. Holst, J.
J., & Gromada, J. 2004, Role of incretin hormones in the regulation of
insulin secretion in diabetic and nondiabetic humans. American Journal of
Physiology-Endocrinology and Metabolism, 287(2), E199-E206. https://doi.org/10.1152/ajpendo.00002.2004
[11]. Drucker, D.
J. 2006, The biology of incretin hormones. Cell Metabolism, 3(3),
153-165. https://doi.org/10.1016/j.cmet.2006.01.004
[12]. Deacon, C.
F. 2004, Therapeutic strategies based on glucagon-like peptide 1. Diabetes,
53(1), 2181-2189. https://doi.org/10.2337/diabetes.53.9.2181
[13]. Flint, A.,
Raben, A., Astrup, A., & Holst, J. J. 1998, Glucagon-like peptide 1
promotes satiety and suppresses energy intake in humans. Journal of Clinical
Investigation, 101(3), 515-520. https://doi.org/10.1172/JCI990
[14]. Yip, R. G.,
& Wolfe, M. M. 2000, GIP biology and fat metabolism. Life Sciences,
66(2), 91-103. https://doi.org/10.1016/S0024-3205(99)00543-2
[15]. Meier, J.
J., & Nauck, M. A. 2010, GIP as a potential therapeutic agent? Hormone
and Metabolic Research, 42(10), 791-795. https://doi.org/10.1055/s-0030-1262893
[16]. Drucker, D.
J., & Nauck, M. A. 2006, The incretin system: Glucagon-like peptide-1
receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The
Lancet, 368(9548), 1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5
[17]. Bailey, C.
J., & Turner, R. C. 1996, Metformin. New England Journal of Medicine,
334(9), 574-579. https://doi.org/10.1056/NEJM199602293340906
[18]. Wulffelé,
M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T.
2004, The effect of metformin on blood pressure, plasma cholesterol, and
triglycerides in type 2 diabetes mellitus: A systematic review. Journal of
Clinical Pharmacology, 57(6), 859-866. https://doi.org/10.1046/j.1365-2125.2004.02078.x
[19]. Goda, M.,
& Kadowaki, T. 2013, Teneligliptin for the treatment of type 2 diabetes. Clinical
Pharmacokinetics, 52(9), 741-754. https://doi.org/10.1007/s40262-013-0073-9
[20]. Morishita,
R., & Nakagami, H. 2015, Teneligliptin: Expectations for its pleiotropic
action. Expert Opinion on Pharmacotherapy, 16(3), 417-426. https://doi.org/10.1517/14656566.2015.995617
[21]. Mulvihill,
E. E., & Drucker, D. J. 2014, Pharmacology, physiology, and mechanisms of
action of dipeptidyl peptidase-4 inhibitors. Endocrine Reviews, 35(6),
992-1019. https://doi.org/10.1210/er.2014-1035
[22]. Ahren, B.
2011, DPP-4 inhibition and the path to clinical proof. Frontiers in
Endocrinology, 2, 22. https://doi.org/10.3389/fendo.2011.00022
[23]. Lin, S. H.,
Cheng, P. C., Te Tu, S., et al. 2018, Effect of metformin monotherapy on serum
lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes
mellitus: A cohort study. PeerJ, 6, e4578. https://doi.org/10.7717/peerj.4578
[24]. He, L. 2020,
Metformin and systemic metabolism. Trends in Pharmacological Sciences, 41(11),
868–881. https://doi.org/10.1016/j.tips.2020.09.008
[25]. Gillani, S.
W., Ghayedi, N., Roosta, P., et al. 2021, Effect of metformin on lipid profiles
of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Journal
of Pharmacy and Bioallied Sciences, 13(1), 76–82. https://doi.org/10.4103/jpbs.JPBS_113_20
[26]. Tarry-Adkins,
J. L., Grant, I. D., Ozanne, S. E., et al. 2021, Efficacy and side effect
profile of different formulations of metformin: A systematic review and
meta-analysis. Diabetes Therapy, 12(7), 1901–1914. https://doi.org/10.1007/s13300-021-01122-3
[27]. Fisman, E.
Z., & Tenenbaum, A. 2015, Antidiabetic treatment with gliptins: Focus on
cardiovascular effects and outcomes. Cardiovascular Diabetology, 14(1),
129. https://doi.org/10.1186/s12933-015-0273-5
[28]. Batta
Raghuveer, & Nama, N. 2020, Efficacy of teneligliptin with metformin in
Type 2 diabetes mellitus patients. National Journal of Physiology, Pharmacy
and Pharmacology, 10(8), 1–4. https://doi.org/10.5455/njppp.2020.10.042302020080520
[29]. Ferreira,
M. A., Gomes, A. P., de Moraes, A. P., et al. 2017, Green tea extract
outperforms metformin in lipid profile and glycaemic control in overweight
women: A double-blind, placebo-controlled, randomized trial. Clinical
Nutrition ESPEN, 22, 1–6. https://doi.org/10.1016/j.clnesp.2017.10.008
[30]. Morishita,
R., & Nakagami, H. 2015, Teneligliptin: Expectations for its pleiotropic
action. Expert Opinion on Pharmacotherapy, 16(3), 417–426.
https://doi.org/10.1517/14656566.2015.1008527
